Hennion & Walsh Asset Management, Inc. Iveric Bio, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$26.24 - $39.63 $18,709 - $28,256	-713 Reduced 0.9%	78,233 $3.08 Million
Q1 2023 Apr 20, 2023	BUY	$18.67 - $24.56 $63,590 - $83,651	3,406 Added 4.51%	78,946 $1.92 Million
Q4 2022 Jan 12, 2023	BUY	$17.24 - $23.95 $529,578 - $735,696	30,718 Added 68.53%	75,540 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $104,904 - $207,464	11,160 Added 33.15%	44,822 $804,000
Q2 2022 Jul 19, 2022	BUY	$9.12 - $18.9 $306,997 - $636,211	33,662 New	33,662 $324,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.